Psychiatric Annals

Psychiatry in the News 

Psychiatry in the News

Abstract

Psychiatry in the News summarizes consumer-oriented media reports on psychiatry and topics related to psychiatry. We recognize that for our readers, keeping abreast of new clinical information is a challenge, leaving little time to review the information, good and bad, that media outlets supply to consumers. Our purpose is to help keep you informed about subjects that your patients might read or hear and question you about.

Please note that publication of the reports in this department does not imply endorsement of the methods or systems described.

We hope you find this department both informative and entertaining. As always, we welcome your comments and contributions; please e-mail marcher@slackinc.com.

FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs

The U.S. Food and Drug Administration recently states that it will now require manufacturers of ‘conventional’ antipsychotic drugs to make safety-related changes to prescribing information to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia. [see more news...]

Abstract

Psychiatry in the News summarizes consumer-oriented media reports on psychiatry and topics related to psychiatry. We recognize that for our readers, keeping abreast of new clinical information is a challenge, leaving little time to review the information, good and bad, that media outlets supply to consumers. Our purpose is to help keep you informed about subjects that your patients might read or hear and question you about.

Please note that publication of the reports in this department does not imply endorsement of the methods or systems described.

We hope you find this department both informative and entertaining. As always, we welcome your comments and contributions; please e-mail marcher@slackinc.com.

FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs

The U.S. Food and Drug Administration recently states that it will now require manufacturers of ‘conventional’ antipsychotic drugs to make safety-related changes to prescribing information to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia. [see more news...]

Psychiatry in the News summarizes consumer-oriented media reports on psychiatry and topics related to psychiatry. We recognize that for our readers, keeping abreast of new clinical information is a challenge, leaving little time to review the information, good and bad, that media outlets supply to consumers. Our purpose is to help keep you informed about subjects that your patients might read or hear and question you about.

Please note that publication of the reports in this department does not imply endorsement of the methods or systems described.

We hope you find this department both informative and entertaining. As always, we welcome your comments and contributions; please e-mail marcher@slackinc.com.

FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs

The U.S. Food and Drug Administration recently states that it will now require manufacturers of ‘conventional’ antipsychotic drugs to make safety-related changes to prescribing information to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia. [see more news...]

10.3928/00485713-20080701-07

Sign up to receive

Journal E-contents